|Articles|August 2, 2013

EMA Seeks Public Consult on Bioequivalence Concept Paper

Author(s)BioPharm International Editors

EMA releases concept paper on development of product-specific guidance on demonstration of bioequivalence.

RELATED ARTICLES

The European Medicines Agency has released its draft concept paper on the development of development of product-specific guidance on demonstration of bioequivalence. Public comments are open until September 30.

EMA plans to develop product-specific guidance to enable a consistent approach to the assessment of applications based on bioequivalence data across various submission routes to help companies design study programs that meet European Union regulations. The guidance will be based on EMA’s guideline on the investigation of bioequivalence.

Source: European Medicines Agency
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001866.jsp&mid=WC0b01ac058004d5c1

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!